Daniel Lynch is listed as an executive officer and director on 20 SEC Form D filings by 12 issuers between May 2009 and Jul 2024. Largest by amount reported sold: Cardurion Pharmaceuticals, Inc. (Burlington, MA — biotechnology — 2024; $260.4M reported sold to 19 investors), 2seventy bio, Inc. (Cambridge, MA — biotechnology — 2022; $170M reported sold to 22 investors), Xilio Therapeutics, Inc. (Waltham, MA — biotechnology — 2021; $95M reported sold to 17 investors), bluebird bio, Inc. (Cambridge, MA — biotechnology — 2012–2021; $75M reported sold to 17 investors), RaNA Therapeutics, LLC (Cambridge, MA — biotechnology — 2015; $63.8M reported sold to 27 investors) and 7 more (all listed below).
What this means That is a lot of deals — 12 separate companies raised money with this person listed as executive officer and director, over about 15 years. Across those companies the filings report $878.3M sold in total.
Listed alongside Amir Nashat (4 shared filings), Nick Leschly (4 shared filings), Wendy L. Dixon (4 shared filings), Jane V. Henderson (3 shared filings), Jean-Francois Formela (3 shared filings) and 111 others.
What this means These are the other officers, directors or promoters the companies named on the same forms — the team around Daniel. Each name links to their own page.
The issuers belong to 2 sponsor groups: Bluebird (2 issuers, $245M reported sold, 2010–2022) and Third Rock (7 issuers, $2.62B reported sold, 2010–2026).
What this means This person is listed across more than one sponsor team; each group page shows that team's full track record.
Public records searched: federal courts (CourtListener / RECAP), SEC enforcement releases, state securities regulators (AK, AL, AR, AZ, CA, CT, DE, FINRA, GA, HI, ID, IL, KS, KY, LA, MA, MD, ME, MI, MO, MS, MT, NASAA, NC, ND, NH, NM, NV, OK, OR, PA, RI, SC, SD, TN, TX, VT, WA, WI, WV, WY) — 4 bankruptcy cases matching the name listed in Key records below.
What this means 4 records came back. Each one is listed below with a link to the original document and a line saying why it matched. A name match is not proof it is the same person or company — read the why line and the document. Being sued or named in a release is an accusation, not a finding.
We compared 20 public filings for Daniel Lynch and found 12 differences, 1 worth asking the sponsor about: Form D filed 303 days after the first sale; and more below.
What this means These are differences between the sponsor's own SEC filings — both values, dates and sources are listed in Key records, section 4. Most have ordinary explanations; ask the sponsor.